CN112236428B - 抗增殖化合物及其用途 - Google Patents

抗增殖化合物及其用途 Download PDF

Info

Publication number
CN112236428B
CN112236428B CN201980036896.XA CN201980036896A CN112236428B CN 112236428 B CN112236428 B CN 112236428B CN 201980036896 A CN201980036896 A CN 201980036896A CN 112236428 B CN112236428 B CN 112236428B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
certain embodiments
compound
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980036896.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN112236428A (zh
Inventor
亨利·于
M·克拉克
G·贝米斯
M·博伊德
K·钱杜帕特拉
P·克里尔
邓红波
董慧君
W·多施
R·R·胡沃
M·A·小约翰逊
S·库尔卡尼
M·佩尼
S·隆金
D·塔克莫托
唐青
N·D·瓦尔
王天生
D·J·劳弗
李磐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Vertex Pharmaceuticals Inc
Original Assignee
Merck Patent GmbH
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH, Vertex Pharmaceuticals Inc filed Critical Merck Patent GmbH
Publication of CN112236428A publication Critical patent/CN112236428A/zh
Application granted granted Critical
Publication of CN112236428B publication Critical patent/CN112236428B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201980036896.XA 2018-04-24 2019-04-23 抗增殖化合物及其用途 Active CN112236428B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862661719P 2018-04-24 2018-04-24
US62/661,719 2018-04-24
PCT/US2019/028607 WO2019209759A1 (en) 2018-04-24 2019-04-23 Antiproliferation compounds and uses thereof

Publications (2)

Publication Number Publication Date
CN112236428A CN112236428A (zh) 2021-01-15
CN112236428B true CN112236428B (zh) 2025-04-01

Family

ID=66655429

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980036896.XA Active CN112236428B (zh) 2018-04-24 2019-04-23 抗增殖化合物及其用途

Country Status (26)

Country Link
US (4) US10815225B2 (cg-RX-API-DMAC7.html)
EP (2) EP3784666B1 (cg-RX-API-DMAC7.html)
JP (2) JP7304892B2 (cg-RX-API-DMAC7.html)
KR (1) KR102813581B1 (cg-RX-API-DMAC7.html)
CN (1) CN112236428B (cg-RX-API-DMAC7.html)
AR (1) AR114496A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019261308B2 (cg-RX-API-DMAC7.html)
CA (1) CA3098335A1 (cg-RX-API-DMAC7.html)
CY (1) CY1125433T1 (cg-RX-API-DMAC7.html)
DK (2) DK3784666T3 (cg-RX-API-DMAC7.html)
ES (2) ES2987356T3 (cg-RX-API-DMAC7.html)
FI (1) FI4043460T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20241163T1 (cg-RX-API-DMAC7.html)
HU (2) HUE058746T2 (cg-RX-API-DMAC7.html)
IL (2) IL301501B2 (cg-RX-API-DMAC7.html)
LT (1) LT3784666T (cg-RX-API-DMAC7.html)
MX (1) MX2020011089A (cg-RX-API-DMAC7.html)
PL (2) PL3784666T3 (cg-RX-API-DMAC7.html)
PT (2) PT4043460T (cg-RX-API-DMAC7.html)
RS (1) RS63281B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202009500QA (cg-RX-API-DMAC7.html)
SI (1) SI3784666T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200308T1 (cg-RX-API-DMAC7.html)
TW (1) TWI813673B (cg-RX-API-DMAC7.html)
WO (1) WO2019209759A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006071B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301501B2 (en) 2018-04-24 2024-10-01 Vertex Pharma Antiproliferation compounds and uses thereof
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
WO2020236834A1 (en) * 2019-05-20 2020-11-26 Seshadri Raju Modified z stents for iliac vein stenting
CN115103840B (zh) 2019-12-20 2025-07-22 拜耳公司 取代的噻吩甲酰胺、噻吩甲酸及其衍生物
US20240132464A1 (en) * 2022-09-28 2024-04-25 Accutar Biotechnology Inc. Heterocyclic compounds as e3 ligase inhibitors
WO2025223536A1 (zh) * 2024-04-26 2025-10-30 正大天晴药业集团股份有限公司 稠合双环化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114179A1 (en) * 2009-04-02 2010-10-07 Mitsubishi Tanabe Pharma Corporation 3-[1,4]oxazepane-4-pyrimidone derivatives
CN102753528A (zh) * 2009-12-04 2012-10-24 霍夫曼-拉罗奇有限公司 作为单胺重摄取抑制剂的二苯基氮杂*衍生物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
DE19840028A1 (de) 1998-09-02 2000-03-09 Max Planck Gesellschaft Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung
OA12118A (en) 1999-12-10 2006-05-04 Pfizer Prod Inc PyrroloÄ2,3-dÜpyrimidine compounds.
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
KR100833371B1 (ko) 2001-04-27 2008-05-28 젠야쿠코교가부시키가이샤 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001766A (es) 2002-08-14 2005-08-19 Atugen Ag Uso de proteina quinasa n beta.
WO2004089925A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
WO2005007623A2 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
HRP20140975T1 (hr) 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
DE102008031517A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
US8163763B2 (en) 2008-07-31 2012-04-24 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP3256132A1 (en) 2015-02-13 2017-12-20 Merck Patent GmbH Pyrimidine derivatives for use in the treatment of cancer
IL301501B2 (en) 2018-04-24 2024-10-01 Vertex Pharma Antiproliferation compounds and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114179A1 (en) * 2009-04-02 2010-10-07 Mitsubishi Tanabe Pharma Corporation 3-[1,4]oxazepane-4-pyrimidone derivatives
CN102753528A (zh) * 2009-12-04 2012-10-24 霍夫曼-拉罗奇有限公司 作为单胺重摄取抑制剂的二苯基氮杂*衍生物

Also Published As

Publication number Publication date
KR102813581B1 (ko) 2025-05-29
US12195453B2 (en) 2025-01-14
IL301501B2 (en) 2024-10-01
ES2919572T3 (es) 2022-07-27
AR114496A1 (es) 2020-09-09
AU2019261308A1 (en) 2020-10-22
EP3784666B1 (en) 2022-03-16
HRP20220710T1 (hr) 2022-07-22
PT4043460T (pt) 2024-09-10
EP4043460A1 (en) 2022-08-17
AU2019261308B2 (en) 2022-09-08
SG11202009500QA (en) 2020-11-27
HUE058746T2 (hu) 2022-09-28
PL3784666T3 (pl) 2022-07-18
TW202012400A (zh) 2020-04-01
CY1125433T1 (el) 2025-05-09
TWI813673B (zh) 2023-09-01
CN112236428A (zh) 2021-01-15
FI4043460T3 (fi) 2025-05-09
IL301501B1 (en) 2024-06-01
IL278142B1 (en) 2023-07-01
US20250188070A1 (en) 2025-06-12
CA3098335A1 (en) 2019-10-31
ES2987356T3 (es) 2024-11-14
HUE067936T2 (hu) 2024-11-28
IL278142A (en) 2020-11-30
PT3784666T (pt) 2022-06-06
SMT202200308T1 (it) 2022-09-14
JP2023101824A (ja) 2023-07-21
BR112020020940A2 (pt) 2021-03-02
SI3784666T1 (sl) 2022-07-29
DK3784666T3 (da) 2022-06-20
MX2020011089A (es) 2020-11-06
ZA202006071B (en) 2024-01-31
WO2019209759A1 (en) 2019-10-31
IL301501A (en) 2023-05-01
LT3784666T (lt) 2022-06-10
EP3784666A1 (en) 2021-03-03
EP4043460B1 (en) 2024-06-05
US20230150993A1 (en) 2023-05-18
KR20210005151A (ko) 2021-01-13
US10815225B2 (en) 2020-10-27
PL4043460T3 (pl) 2024-10-28
US20190322658A1 (en) 2019-10-24
JP7304892B2 (ja) 2023-07-07
DK4043460T3 (da) 2024-08-26
IL278142B2 (en) 2023-11-01
JP2021522242A (ja) 2021-08-30
RS63281B1 (sr) 2022-06-30
HRP20241163T1 (hr) 2024-11-22
US11440907B1 (en) 2022-09-13

Similar Documents

Publication Publication Date Title
US11780837B2 (en) CXCR4 inhibitors and uses thereof
KR102813581B1 (ko) 항증식 화합물 및 이의 용도
US20210363139A1 (en) Cxcr4 inhibitors and uses thereof
US11325924B2 (en) Modulators of Sestrin-GATOR2 interaction and uses thereof
WO2024054603A1 (en) Heterobifunctional compounds and methods of treating disease
CN113164419A (zh) Eif4e抑制剂和其用途
US20240174665A1 (en) Cdk2 inhibitors and uses thereof
HK40078355B (en) Antiproliferation compounds and uses thereof
HK40078355A (en) Antiproliferation compounds and uses thereof
RU2811969C2 (ru) Антипролиферативные соединения и их применения
HK40047065A (en) Antiproliferation compounds and uses thereof
HK40047065B (en) Antiproliferation compounds and uses thereof
WO2024264070A2 (en) Akt inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Henry Yu

Inventor after: R. R. Hoover

Inventor after: M. A. Johnson Jr

Inventor after: S. Kurkani

Inventor after: M. Painy

Inventor after: S. Longjin

Inventor after: D. Tacomoto

Inventor after: Tang Qing

Inventor after: N.D. Val

Inventor after: Wang Tiansheng

Inventor after: Lauffer David Jeffrey

Inventor after: M. Clark

Inventor after: Li Pan

Inventor after: Bemis Guy

Inventor after: M. Boyd

Inventor after: K. Chandu Patra

Inventor after: P. Kriel

Inventor after: Deng Hongbo

Inventor after: Dong Huijun

Inventor after: W. Give more

Inventor before: Henry Yu

Inventor before: R. R. Hoover

Inventor before: M. A. Johnson Jr

Inventor before: S. Kukami

Inventor before: M. Painy

Inventor before: S. Longjin

Inventor before: D. Tacomoto

Inventor before: Tang Qing

Inventor before: N.D. Val

Inventor before: Wang Tiansheng

Inventor before: Lauffer David Jeffrey

Inventor before: M. Clark

Inventor before: Li Pan

Inventor before: Bemis Guy

Inventor before: M. Boyd

Inventor before: K. Chandu Patra

Inventor before: P. Kriel

Inventor before: Deng Hongbo

Inventor before: Dong Huijun

Inventor before: W. Give more

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20390623

TG01 Patent term adjustment